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SUMMARY. The use of automated blood processors in
combination with bottom and top blood containers has
been found to improve the standardization and quality of
blood components. A study was performed to validate
a new type of processor (OptipressÒ II) and compare
its performance with a first generation processor
(Optipress Ò I).
Primary separation on the Optipress II was investi-
gated on 570 mL (6 10%) of anticoagulated blood
in a nonpaired study. In addition, the quality of the
products in routine production was compared between
the results of the Optipress I and Optipress II. The
whole blood units were kept overnight at room tempera-
ture (20 6 2 8C). Separation was performed under con-
ditions to obtain 55 mL buffy coats with a 50%
haematocrit (ht). Platelet concentrate preparation was
investigated in a paired study and compared to
the routine manual method using PAS II additive solu-
tion. Parameters studied were volume, red cell, white
cell and platelet counts, ht, haemoglobin (hb, total and
free).
Primary separation was more efficient in the Optipress
II because the platelet count was lower in the erythrocyte
concentrates (P < 0·0001), platelets were lower in plasma
(P< 0·0001) and platelet counts were higher in buffy
coats (P < 0·0001). Buffy coat volume showed less
variation (Optipress II VC ¼ 4%, Optipress I VC ¼
7·4%). Secondary separation did not show differences
between the Optipress II and manual method but was
advantageous because of the automatic termination of
the procedure.
Further improvement of standardization in blood com-
ponent preparation is possible with an automated blood
processor, leading to improvement of the quality of blood
products for patient care.
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Blood component preparation has become a routine
procedure worldwide (Heaton et al., 1997). Basically
whole blood is collected in anticoagulant solutions and
centrifuged to produce components adapted to the user’s
need. The aim can be to optimize buffy coat separation,
to maximize plasma harvest or to maximize red cell
recovery with an acceptable plasma harvest. Generally
the recovered red cells are suspended in additive solution
(AS) (Lovric et al., 1977; Ho¨gman et al., 1978) to
optimize storage conditions and maximize plasma har-
vest. A similar approach of AS addition is increasingly
applied to platelet concentrates prepared from buffy
coats (Gulliksson et al., 1995; van Rhenen et al., 1995).
An ever increasing quality of blood components can
thus be offered to the hospitals, produced in an efficient
way (Molijn et al., 1994). The basic principle of this
development is standardization. The whole blood volume
is collected within specified borders (6 10%) and the
component preparation is performed according to GMP
rules and standardized within specified limits regarding
volume, haematocrit, white cell and platelet count.
The use of bottom and top containers in combination
with automated component separation devices has been
found to improve further standardization and the quality
of blood components (Heaton et al., 1997).
In this study we compared the performance of one
of the first component separation devices available
(OptipressÒ I) with a recently developed automated
device (OptipressÒ II) to investigate whether standardi-
zation and quality of blood components could be
improved further.
MATERIALS AND METHODS
Blood packs
Optipac Ò (Baxter Inc., La Chaˆtre, France) was used for
collecting 500 6 50 mL blood from volunteer donors.
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The blood pack consists of a primary ‘bottom and top’
bag filled with 70 mL CPD anticoagulant solution, a
secondary conventional bag filled with 110 mL SAG-M
solution and an empty transfer bag. Packs are made of PL
2209 plastic material.
Blood processors
A machine called Optipress II was developed for auto-
mated blood processing by Baxter R and D, Nivelles,
Belgium. This device incorporates the functions avail-
able on its predecessor (Optipress I) but is enhanced by
several modifications. For instance the machinery is not,
as is the Optipress I, dependent on compressed air.
Furthermore, the detection of the interface between
cells and plasma has been improved and automated
sealing can be performed.
Study design
The study was structured in four phases:
1 equipment performance validation for the primary and
the secondary separation;
2 determination of the maximum press plate force
setting;
3 Optipress II efficiency study;
4 comparison with Optipress I during routine production.
Primary separation study
Thirty-one blood units of 500 mL 6 10% were collected
from volunteer donors in 70 mL CPD anticoagulant
solution using a ‘bottom and top’ system (Optipac).
Selection of donors as well as blood donation procedures
were based on local standard practices. All blood units
were actively cooled to 20 6 2 8C and kept overnight at
room temperature (20 6 2 8C) before they were centri-
fuged at high speed (4657g) for 10 min.
The Optipress II was equipped with a 500 Opti 30 mid
backplate for the primary separation of 570 mL of anti-
coagulated blood using the following parameters: buffy
coat volume: 55 mL, buffy coat level: 6·7, pressplate
force: 25 kg. The same Optipress II was equipped with a
flat backplate for the secondary separation of platelets
from pooled buffy coats using the following parameters:
time: 5 min, sensitivity: 40, red cell level (RCL): 40,
pressplate force: 8 kg.
The results used for comparison in the routine produc-
tion study were those obtained in routine quality testing
of the blood components produced on Optipress I during
quarters 3 and 4 in 1995 and produced on Optipress II
during quarters 3 and 4 in 1997.
Primary separation was performed under condi-
tions defined to obtain 55 mL buffy coats with a 50%
haematocrit.
Sampling was performed to obtain the following data:
1 whole blood donation: volume, red blood cell/white
blood cell/platelet counts, haematocrit, total haemoglo-
bin and free haemoglobin;
2 red cell concentrate: volume, total haemoglobin, red
blood cell/white blood cell/platelet counts and haemato-
crit. Free haemoglobin was assessed at day 1 (n ¼ 31),
day 14 (n ¼ 31) and day 35 of storage (n ¼ 10);
3 plasma product: volume, total haemoglobin concen-
tration, white cells and platelet counts;
4 buffy coat product: volume, red blood cell/white blood
cell/platelet counts, total haemoglobin and haematocrit.
Automatic cell counting was performed for haemoglo-
bin, red blood cell, white blood cell and platelets with a
Cell Dyn 3500 cell counter (Abbott, Chicago, USA).
Leukocyte counting in plasma was performed in the
Nageotte counting chamber technique.
Secondary separation study
This study was designed as a paired study comparing 12
separation processes on Optipress II vs. 12 manual sepa-
ration processes. The Optipress II was equipped with a
flat backplate for the separation of platelets from pooled
buffy coats using the following parameters: time: 5 min,
sensitivity: 40, red cell level (RCL): 40, pressplate force:
8 kg.
The contents of 10 ABO-identical CPD buffy coats
were mixed and split equally into two 600-mL pooling
containers. A volume of < 300 mL of acetate containing
additive solution (PAS II) was added to each pool
(containing the equivalent of five buffy coats). The
pools were sampled for cell counts and haematocrit
measures, connected to a platelet storage container and
centrifuged (655g) for 5 min. From each pair of pools one
platelet concentrate was prepared using the Optipress II
as extractor while the other pool was processed with a
manual method using a conventional plasma extractor.
Sealing was in both cases performed with a hand-held
sealer. Each platelet concentrate has been assessed for
volume, all cell counts and free haemoglobin at the time
of separation.
Determination of the maximum pressplate force setting
Primary separation was performed with machine settings
defined as mentioned above except for the press plate
force. The pressplate force was adjusted to the 50-kg
setting instead of the 25-kg setting evaluated in the
primary separation study in order to investigate whether
the speed of blood processing could be increased. The
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sampling was performed as mentioned above in the
primary separation study.
Optipress II efficiency study
Upon definition of the force parameter setting mentioned
for the primary separation study, Optipress II machines
were set with 25 kg pressplate force.
The machines were then used on a routine basis for 6
weeks to allow an estimation of machine efficiency and
its impact on product quality.
Comparison has been established with the Optipress I
equipment on the following aspects: duration of the
separation process, total time for the centrifugation, the
separation and the tube sealing of a quantity of blood
packs corresponding to eight centrifuge machine loads
(96 units) and the scrap levels of the separation process.
Comparison with Optipress I during routine production
The Optipress II was then used in production with
parameter settings defined during the primary separation
study.
Routine quality control results of the blood compo-
nents produced with the Optipress II during quarters
3 and 4 in 1997 were compared with the same data
generated during the routine usage of the Optipress I
during quarters 3 and 4 in 1995.
Data treatment
For the primary separation study the data of routine
production on Optipress II were compared to those
obtained from quality control testing during the last
two quarters of 1995 using a t-test (difference between
two means Statistica for Windows, version 4·5).
For the secondary separation study platelet character-
istics were evaluated using a t-test (paired two samples
for means Microsoft Excel, version 5·0). The Optipress II
efficiency study results were analysed using a t-test
(two samples for means Microsoft Excel, version 5·0).
P values for the comparison of routine results were
calculated using a significance test difference between
two means (Statistica for Windows version 5·1 StatSoft
Inc.).
RESULTS
Primary separation study
The results of the primary separation study with Opti-
press II are shown in Table 1. Comparison of the quality
control results in routine production of Optipress I and of
Optipress II is shown in Table 2.
Altough routine quality control data do not include cell
counts on donation and consequently do not allow us
to draw definite conclusions on the trial results, the
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Table 1. Results of the primary
separation study with the OptipressÒ II Optipress Ò II
Units n Mean SD
Whole blood volume mL 31 561·9 8
leukocytes 109 per unit 31 3·34 0·88
platelets 109 per unit 31 122 26
erythrocytes 1012 per unit 31 2·35 0·19
Red cell concentrate volume mL 31 311·5 13·3
leukocytes 109 per unit 31 0·59 0·46
platelets 109 per unit 31 1·35 0·37
erythrocytes 1012 per unit 31 2·04 0·18
haematocrit % 31 61 2
free Hb (day 35) mg per unit 31 77·05 26·96
Plasma volume mL 31 307·8 14·58
leukocytes 106 per unit 31 1·19 1·17
platelets 109 per unit 31 3·36 1·01
free Hb mg per unit 31 4·78 3·85
Buffy coats volume mL 31 54·4 1·7
leukocytes 109 per unit 31 2·77 0·58
platelets 109 per unit 31 91·7 18·3
erythrocytes 1012 per unit 31 0·29 0·02
haematocrit % 31 51·2 3·7
following appears from the data analysis:
X The platelet content of red cell concentrates
(0·7 6 0·7 · 109 per unit) produced with the new extrac-
tor in routine practice is significantly (P < 0·0001) lower
than the values with Optipress I (3·20 6 0·08 · 109 per
unit).
X Haemolysis in the red cell concentrates was assessed
by measure of free haemoglobin and was found to be
within acceptable limits with respective average values
of 0·05% (n ¼ 31 at day 1), 0·14% (n ¼ 31 at day 14) and
0·22% (n ¼ 10 at day 35).
X The platelet content of the plasma fractions produced
routinely with the Optipress II appears significantly
lower than that seen with the Optipress I (5 6 2·6 · 109
platelets per unit P< 0·0001).
Finally, the new separator has a better reproducibility
(P < 0·005 – Fisher test) in buffy coat volume (55 6 2 mL
compared to 54·0 6 4·0 mL) than the actual model in use
in the bloodbank laboratory.
Platelet concentrate preparation study
Statistical analysis shows equivalence of data obtained
on platelet concentrates separated with the Optipress II
compared to platelet concentrates prepared using the
manual method from the bloodbank laboratory.
Quality of blood components prepared with pressplate
force at maximum setting of 50 kg
Comparing results on blood quality components pro-
duced with the maximum pressplate force (50 kg setting
value) with similar data obtained from the first part of the
Optipress II study revealed a greater variation in buffy
coat volume, significantly higher platelet content and
haemolysis in the red cell concentrates (data not shown).
Duration of the separation process
Mean separation time for the Optipress II is 340 s
compared to 324 s for the similar operation on the
Optipress I, but statistical analysis shows no signifi-
cant difference either in the distribution or in the mean
value.
Total time for the separation processing
The total time to process eight centrifuge loads using the
Optipress II was compared to the time needed for the
same operation using the Optipress I. This comparison
(1 h, 24 min and 10 s for the Optipress II and 1 h 24 min
and 36 s for the Optipress I) does not reveal a difference
between the two machines.
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Table 2. Comparison of the quality control results in routine production of the Optipress Ò I and of the OptipressÒ II
Optipress Ò I Optipress Ò II
Units n Mean SD n Mean SD P
Whole blood volume mL 42780 574 10 43·784 568 10 < 0·0001
leukocytes 109 per unit
platelets 109 per unit
erythrocytes 1012 per unit
Red cell concentrate volume mL 474 307 17 520 302 16 < 0·0001
leukocytes 109 per unit 474 0·52 0·36 520 0·64 0·39 < 0·0001
platelets 109 per unit 474 3·2 0·8 520 0·7 0·7 < 0·0001
erythrocytes 1012 per unit 474 2 0·19 520 1·99 0·19 NS
haematocrit % 474 60 3 520 59 2 < 0·0001
free Hb (day 35) mg per unit 120 67·8 36·3 135 21 16 < 0·0001
Plasma volume mL 474 319 17 520 314 17 < 0·0001
leukocytes 106 per unit 120 2·6 3 135 2·6 2·7 NS
platelets 109 per unit 475 5 2·6 520 3 1·7 < 0·0001
free Hb mg per unit 475 4·7 5·1 519 5·2 4·9 NS
Buffy coats volume mL 490 54 4 515 55 2 < 0·0001
leukocytes 109 per unit 490 3·03 0·73 515 2·28 0·64 < 0·0001
platelets 109 per unit 490 96 20 515 106 25 < 0·0001
erythrocytes 1012 per unit 490 0·29 0·04 515 0·30 0·03 < 0·0001
haematocrit % 420 50 4 515 49 3 < 0·0001
Scrap level comparison
A comparison of defect rates was made over a period of 6
weeks during which the Optipress II was used on a
routine basis against data gathered in 1996 during use
of Optipress I and manual tubes sealing for an equivalent
period of time (see Table 4).
Two parameters were used for the comparison:
1 incidence of leaking seals;
2 incidence of incorrect position of the buffy coat inter-
face level at the end of the separation process resulting in
inappropriate buffy coat composition (haematocrit, white
blood cells, red blood cells and platelet content).
The results of the comparison are shown in Table 3.
DISCUSSION
The application of good manufacturing practices requires
standardized methods of production. The use of auto-
mated blood processing techniques reduces the impact of
human factors in blood component preparation and
improves standardization and quality of blood products.
The primary separation process using bottom and top
containers allowed the production of blood components
with characteristics within tight limits. Using the second
generation blood processor, red cell concentrates were
produced with a mean leucocyte reduction of 82%, a
platelet reduction of 99% and a red cell loss of only 13%
compared with whole blood (Heaton et al., 1997). The
platelet concentrates produced from buffy coats con-
tained 63% of the original whole blood platelet content
and only 3% of residual leucocytes (without filtration).
Together with the very low leucocyte and platelet con-
tent of the plasma, a very efficient component separation
is achieved in this way and compares favourably with the
existing literature (Meryman & Hornblower, 1986; Loos,
1988; Ho¨gman et al., 1992).
The same second generation blood processor that is
used for primary separation of blood components can be
used for the secondary separation of platelet concentrates
from pooled buffy coats, further reducing the influence of
the human factor on the variability of product character-
istics in routine large-scale platelet concentrate produc-
tion (Pietersz et al., 1990; Rebulla et al., 1990; American
Association of Blood Banks, 1994; Council of Europe,
1995; Zoon et al., 1996).
The results obtained demonstrate the advantage of a
full separation process of automation with a drastic
reduction of tube sealing defects. The improvement in
the optical detection system also has a positive effect on
the consistency of the buffy coat contents.
Further improvements in machine efficiency can still
be made. However, the quality of blood components
prepared with pressplate force at maximum setting of
50 kg did not result in optimal products. Further optimi-
zation of the operating parameters and some adaptations
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Table 3. Characteristics of five donor unit platelet concentrates produced by a blood processor in comparison with the manual
method (n ¼ 12)
Plt conc. Plt conc. Plt conc. Plt conc. Plt conc.
volume RBC WBC Plt free Hb
day 1
(mL) (1012 per unit) (109 per unit) (109 per unit) (mg L¹1)
Optipress Ò II
Mean 352·9 0·01 0·09 368·6 101·0
SD 6·4 0·00 0·03 29·5 64·9
Max. 367·2 0·01 0·13 419·2 280·0
Min. 343·4 0·00 0·06 319·7 48·6
Manual method
Mean 353·4 0·01 0·09 368·6 128·8
SD 6·5 0·00 0·03 30·8 84·6
Max. 366·2 0·01 0·13 414·2 370·0
Min. 343·4 0·00 0·05 314·2 57·4
Table 4. Scrap level comparison between the two automated
blood processors
Quantity of Incorrect
donations Leaking seals BC level
1996 OptipressÒ I 9281 41 (0·44%) 178 (1·92%)
Optipress Ò II 9432 0 (0·00%) 12 (0·31%)
of the disposable design may be necessary to operate the
machine at maximum force without inducing higher
haemolysis. On the other hand, the results of the com-
parison on time needed to handle several centrifuge loads
through the separation process may indicate that the
machine processing time is not the limiting factor in
the separation laboratory efficiency.
In conclusion, improvement in standardization of
blood component preparation is possible with an auto-
mated blood processor, leading to improvement in the
quality of blood products for patient care.
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